Impact of ERAS on Postoperative Nausea and Vomiting After Sleeve
Nausea and Vomiting, Postoperative
About this trial
This is an interventional prevention trial for Nausea and Vomiting, Postoperative focused on measuring sleeve gastrectomy, nausea, vomiting
Eligibility Criteria
Inclusion Criteria: * Age: 18-60 years Sex: Both sex ASA Physical Status: II, III. Body mass index: Between 40 and 60 kg/m2. Participants: Patients who are undergoing elective Sleeve Gastrectomy Exclusion Criteria: Patients with hypersensitivity or contraindication to haloperidol, dexamethasone, or ondansetron. Serious complications in the perioperative period (such as shock, cardiac arrest, hemorrhage, needing transfusion). Psychiatric disorder. History of migraine. Use of opioid, hormonal, anti-inflammatory, and antiemetic medication 24 h prior to surgery.
Sites / Locations
- Minia UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
non- enhanced recovery after surgery
enhanced recovery after surgery
All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg, and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.